Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | UBE2M | P61081 | 3/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200222 | 0.88 | LMNA (0.51) | SLC6A9ALDH1A1LMNAGAAUBE2M | |
| SCHEMBL23200134 | 0.88 | TDP1 (0.53) | ALDH1A1POLBLMNAGAAUBE2M | |
| SCHEMBL23200204 | 0.87 | LMNA (0.50) | ALDH1A1LMNAGAAUBE2MDCUN1D1 | |
| SCHEMBL23200139 | 0.87 | GAA (0.54) | SLC6A9ALDH1A1POLBLMNAGAA | |
| SCHEMBL23200154 | 0.87 | LMNA (0.50) | ALDH1A1LMNAGAAUBE2MDCUN1D1 | |
| SCHEMBL23200048 | 0.86 | ALDH1A1 (0.61) | ALDH1A1POLBLMNAUSP2GAA | |
| SCHEMBL23199951 | 0.86 | LMNA (0.53) | ALDH1A1LMNAGAAUBE2MDCUN1D1 | |
| SCHEMBL23699895 | 0.85 | LMNA (0.56) | SLC6A9ALDH1A1POLBLMNAUSP2 | |
| SCHEMBL23699911 | 0.85 | GAA (0.55) | SLC6A9ALDH1A1LMNAGAAUBE2M | |
| SCHEMBL23200025 | 0.85 | UBE2M (0.60) | ALDH1A1POLBLMNAUSP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | claimed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | claimed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | SLC6A9 904/4885ALDH1A1 606/4885POLB 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.